Diasorin received FDA 510(k) clearance and a CLIA waiver for a Group A streptococcus rapid molecular test on its Liaison Nes point-of-care PCR instrument. Diasorin said the assay delivers results in about 15 minutes with less than one minute of hands-on time. The test supports decentralized and outpatient workflows, with room-temperature reagent storage and cloud-connected reporting for real-time data capture. Diasorin also noted it is expanding the Liaison Nes menu, following FDA clearance and CLIA waiver for the platform’s respiratory panel covering influenza A, influenza B, RSV and COVID-19. Diasorin’s strategy includes driving Nes system revenue toward more than $150 million in the U.S. by 2030, with additional assays continuing to move through the regulatory pipeline.